---
layout: default
title: Nitrous Oxide
parent: Model Prediction Only (L5)
nav_order: 974
evidence_level: L5
indication_count: 1
---

# Nitrous Oxide
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **1** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Nitrous Oxide: From Inhaled Anesthetic to Benign Prostatic Hyperplasia

## One-Sentence Summary

Nitrous oxide is an inhaled gas known for anesthesia, analgesia and anxiety relief during procedures. The TxGNN model predicts it may be relevant to **benign prostatic hyperplasia (BPH)**, but the only related evidence is **1 clinical trial** (on biopsy anxiety, not BPH treatment) and **3 old case or device reports**. None of it shows that the drug treats BPH.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated in the US label data provided (commonly known as an inhaled anesthetic/analgesic) |
| Predicted New Indication | Benign prostatic hyperplasia |
| TxGNN Prediction Score | 99.52% |
| Evidence Level | L5 (no study tests nitrous oxide as a BPH treatment; the input pack assigned L4) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 licenses |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the input. Nitrous oxide is generally described as an NMDA-receptor antagonist and inhaled anesthetic/analgesic. Its efficacy for procedural pain and anxiety is established.

The prediction is **not mechanistically convincing**. BPH is driven by androgen-dependent growth of prostate stromal and epithelial tissue, which causes lower urinary tract obstruction. Nothing in nitrous oxide's pharmacology addresses that process.

The high score (0.995) most likely reflects a knowledge-graph artifact, because nitrous oxide is often mentioned alongside urologic procedures. Its only links to the prostate are procedural:
1. It is used as an analgesic or anxiolytic during prostate procedures such as biopsy or prostatectomy.
2. It was historically used as a cryogen in prostate cryotherapy devices.

Neither is a pharmacological treatment of BPH.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT05803096](https://clinicaltrials.gov/study/NCT05803096) | Phase 4 | Completed | 143 | Self-administered nitrous oxide during transrectal prostate biopsy to reduce anxiety and pain. It targets procedural comfort in men undergoing biopsy for suspected prostate cancer, not BPH symptoms. |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9223887](https://pubmed.ncbi.nlm.nih.gov/9223887/) | 1997 | Case report | Masui (Jpn J Anesthesiol) | Anesthetic management of a patient with pure autonomic failure undergoing suprapubic prostatectomy. Nitrous oxide was part of the anesthetic, with no bearing on BPH treatment. |
| [4108916](https://pubmed.ncbi.nlm.nih.gov/4108916/) | 1971 | Case series | Z Prakt Anasthesie Wiederbeleb | Combination anesthesia with methohexital in high-risk urologic patients. Anesthesia technique only. |
| [4171323](https://pubmed.ncbi.nlm.nih.gov/4171323/) | 1968 | Device report | Int Surg | New apparatus for cryotherapy of prostate obstruction. Nitrous oxide appears as a cryogen, not as a drug effect. |

---

## US Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| NDA206009 | Nitrous Oxide (AGL Welding Supply Co., Inc.) | Gas | Not stated in the data provided |
| NDA206009 | Nitrous Oxide (Nitrous Oxide of Canada) | Gas | Not stated in the data provided |
| NDA206009 | Nitrous Oxide (NEXAIR, LLC) | Gas | Not stated in the data provided |
| NDA206009 | Nitrous Oxide (Norco, Inc) | Gas | Not stated in the data provided |
| NDA209989 | Nitrous Oxide (Badger Welding Supplies, Inc.) | Gas | Not stated in the data provided |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The high TxGNN score is not backed by a plausible mechanism or by any study of nitrous oxide as a BPH treatment. The only trial concerns procedural anxiety during prostate biopsy, and the literature consists of decades-old anesthesia and device reports. Nitrous oxide's role around prostate procedures is that of a procedural analgesic or anxiolytic, which is a different question from repurposing it for BPH.

**To proceed, the following is needed:**
- The approved indication text and safety sections (warnings, contraindications) from the US package insert
- Mechanism of action data, for example from DrugBank
- A pharmacological rationale for BPH, or a decision to reframe the question as procedural sedation in urologic procedures, where the evidence is more relevant
- Any prospective study that measures BPH outcomes such as symptom scores or urinary flow
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

